EP0874584A1 - Controle et traitement non invasifs de sujets atteints d'arret cardiaque a l'aide de parametres d'ecg permettant de predire l'issue - Google Patents

Controle et traitement non invasifs de sujets atteints d'arret cardiaque a l'aide de parametres d'ecg permettant de predire l'issue

Info

Publication number
EP0874584A1
EP0874584A1 EP95944683A EP95944683A EP0874584A1 EP 0874584 A1 EP0874584 A1 EP 0874584A1 EP 95944683 A EP95944683 A EP 95944683A EP 95944683 A EP95944683 A EP 95944683A EP 0874584 A1 EP0874584 A1 EP 0874584A1
Authority
EP
European Patent Office
Prior art keywords
subject
frequency
parameter
power spectrum
outcome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP95944683A
Other languages
German (de)
English (en)
Other versions
EP0874584A4 (fr
Inventor
Charles G. Brown
Roger R. Dzwonczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Priority claimed from PCT/US1995/017022 external-priority patent/WO1997024062A1/fr
Publication of EP0874584A1 publication Critical patent/EP0874584A1/fr
Publication of EP0874584A4 publication Critical patent/EP0874584A4/fr
Ceased legal-status Critical Current

Links

Definitions

  • This invention relates generally to the monitoring and treatment of a human or animal subject in cardiac arrest from the electrocardiogram (ECG) of the subject's heart. More particularly, the invention is related to determining clinically useful parameters from the subject's ECG which help guide therapeutic interventions during ventricular fibrillation.
  • ECG electrocardiogram
  • ventricular fibrillation is intended to include asystole which may be considered a form of ventricular fibrillation. Each year more than 350,000 sudden cardiac deaths occur in the United States.
  • Estimation of the elapsed time of ventricular fibrillation can be affected by many factors. These include whether the subject received cardiopulmonary resuscitation prior to the time that the measurement was made and the degree of perfusion of the heart. For example, the subject may be in cardiac arrest clinically but still have some degree of myocardial perfusion when the heart is in a rhythm called "ventricular tachycardia" or “Torsades de Pointes. " Thus, when cardiopulmonary resuscitation generates adequate myocardial perfusion, or if the subject is in a condition with some degree of myocardial perfusion, the metabolic state of the myocardium may not deteriorate as rapidly, despite the fact that the subject is in cardiac arrest clinically.
  • the invention provides a non-invasive method of guiding therapeutic interventions to a subject in cardiac arrest.
  • the method includes connecting electrodes to the body of the subject and detecting from the electrodes an analog electrical potential which is proportional to the electrical potential generated by the subject's heart.
  • the analog potential is sampled for a selected interval of time to obtain a set of time domain samples.
  • a power distribution of the electrical potential is detected by transforming the time domain samples to a frequency domain power spectrum.
  • At least one amplitude parameter of the ECG time-domain signal interval or frequency parameter of the power spectrum is determined and monitored.
  • the parameter or parameters are predictive of a clinically relevant cardiac arrest outcome for the subject. Therapy is administered to the subject as a function of the value of the parameter or parameters.
  • one of the parameters that is predictive of clinically relevant cardiac arrest outcome for the subject is the centroid frequency (F c ) of the power spectrum.
  • another of the parameters that is predictive of clinically relevant cardiac arrest outcome for the subject is the peak power frequency (F p ) of the power spectrum.
  • the combined values of the centroid frequency and the peak power frequency are used as predictive of such cardiac arrest outcomes.
  • a non-invasive method of determining myocardial perfusion and, thus, the metabolic state of the myocardium of a subject in ventricular fibrillation or asystole includes connecting electrodes to the body of the subject and detecting from the electrodes an analog electrical potential which is proportional to the electrical potential generated by the subject's heart.
  • the analog potential is sampled for a selected interval of time to obtain a set of time domain samples and the power distribution of the electrical potential is detected by transforming the time domain samples to a frequency domain power spectrum.
  • At least one amplitude parameter of the ECG time-domain signal interval or frequency parameter of the power spectrum is determined and monitored.
  • the parameter or parameters are predictive of a clinically relevant cardiac arrest outcome for the subject.
  • the parameter or parameters are resolved to an indication of the metabolic state of the myocardium of the subject's heart.
  • the predictive parameter is selected from a group of parameters including centroid frequency of the power spectrum (F c ) and peak power frequency of the power spectrum (F p ).
  • the method according to this aspect of the invention may further include applying therapy to a subject in ventricular fibrillation or asystole, assessing the effect of the therapy on the subject utilizing the determined parameter from the subject's ECG, and guiding further therapy based upon the assessment.
  • the method may further include prescribing a particular therapeutic protocol as a function of centroid frequency and/or peak power frequency of the power spectrum.
  • the apparatus includes an analyzer for determining at least one amplitude parameter of the ECG time-domain signal interval or frequency parameter of the power spectrum of the ECG with the parameter being predictive of a clinically relevant cardiac arrest outcome for the subject and the metabolic state of the myocardium.
  • a processor is provided for resolving the parameter or parameters to a clinically useful characteristic of the subject's heart.
  • the apparatus may be used as a monitor alone or in combination with a defibrillator for administering countershocks or other resuscitators in response to a value of the parameter or combination of parameters.
  • FIG. 1 is a block diagram of an apparatus according to the invention connected with a subject
  • Fig. 2 is a flowchart of a method of treating a subject in ventricular fibrillation, according to the invention
  • Fig. 3 is a block diagram of the apparatus in Fig. 1;
  • Fig. 4 is a block diagram of an alternative apparatus, according to the invention.
  • Fig. 5 is a graph illustrating a receiver operating characteristic curve of the centroid frequency of the power spectrum for an outcome of successful countershock;
  • Fig. 6 is a graph illustrating a receiver operating characteristic curve of the peak power frequency of the power spectrum for an outcome of successful countershock
  • Fig. 7 is a graph illustrating a receiver operating characteristic curve of the average segment amplitude of the power spectrum for an outcome of successful countershock
  • Fig. 8 is a graph illustrating a receiver operating characteristic curve of the average wave amplitude of the power spectrum for an outcome of successful countershock
  • Fig. 9 is a graph illustrating a receiver operating characteristic curve of the centroid frequency of the power spectrum for an outcome of return of spontaneous circulation ever
  • Fig. 10 is a graph illustrating a receiver operating characteristic curve of the peak power frequency of the power spectrum for an outcome of return of spontaneous circulation ever;
  • Fig. 11 is a graph illustrating a receiver operating characteristic curve of the centroid frequency of the power spectrum for an outcome of survival to hospital admission
  • Fig. 12 is a graph illustrating a receiver operating characteristic curve of the peak power frequency of the power spectrum for an outcome of survival to hospital admission
  • Fig. 13 is a graph illustrating a receiver operating characteristic curve of the centroid frequency of the power spectrum for an outcome of survival to hospital discharge.
  • Fig. 14 is a graph illustrating a receiver operating characteristic curve of the peak power frequency of the power spectrum for an outcome of survival to hospital discharge.
  • an apparatus 19 including a predictive parameter determining apparatus 20 and/or a defibrillator 21, and/or a resuscitator 25, is connected to a subject 22, who is assessed to be in cardiac arrest, utilizing conventional internal or external electrodes (Fig. 1). After the apparatus is connected to the subject at 24, a method 23 of treating the subject with apparatus 19 is performed (Fig. 2).
  • Method 23 includes detecting an analog electrical potential which is proportional to the electrical potential generated by the subject's heart and transforming the analog signal into the frequency domain utilizing a fast Fourier transform algorithm, at 26.
  • the technique for converting the analog signal into the frequency domain is disclosed in United States Patent 5,077,667 issued to Charles G. Brown and Roger Dzwonczyk, the disclosure of which is hereby incorporated herein by reference and will not be repeated.
  • the centroid frequency (F c ) and the peak power frequency (F p ) of the power spectrum are determined at 28.
  • the centroid frequency is defined as the X-axis (frequency) coordinate of the center of spectral mass and it is determined by:
  • Peak power frequency (F p ) is the frequency that has the peak power in the power spectrum.
  • the parameters, F c and F p are reported in Hertz and provide an estimate of the frequency distribution of the power of a signal in the spectrum.
  • F c and F p are determined by predictive parameter determining apparatus 20, it is then determined at 30 whether F c and/or F p are equal to or above particular thresholds.
  • the threshold for F p may be set in the range between approximately 3.5 Hz and approximately 7.75 Hz and the threshold for F c may be set in the range between approximately 3.86 Hz and approximately 6.12 Hz.
  • F c and/or F p are equal to or above their respective thresholds, defibrillator 21 is instructed by apparatus 20 at 32 to issue a countershock. It is then determined at 34 whether the countershock resulted in conversion of the ventricular fibrillation to a pulsatile rhythm. If not, then the above-identified procedure is repeated. If conversion to a pulsatile rhythm is achieved, subject 22 is monitored and treated at 35 in order to maintain a pulsatile rhythm. If subject 22 is determined at any time not to have a pulsatile rhythm at 35, the ECG signal from subject 22 is again processed at 26.
  • a non-countershock therapy may be instituted at 36.
  • the alternative therapy is chosen as a function of the value of F c and/or F p .
  • Such alternative therapy may include utilizing drugs, manual cardiopulmonary resuscitation, mechanical resuscitation through the use of resuscitator 25, and/or ventilation/oxy genation .
  • the prescribed intervention is carried out at 38.
  • the electrical potential generated by the subject's heart can be continuously sampled at 26 and processed to obtain the value of F c and/or F p .
  • the intervention protocol is either changed, modified, or kept the same at 36 and carried out at 38.
  • the therapy may be titrated to achieve the appropriate values of the parameters F c and/ or F p .
  • a countershock may be administered at 32.
  • method 23 may be utilized to select the type and dosage of a drug. Method 23 may also be used to determine an optimum rate, force, and/or depth of compression of manual or mechanical CPR, or to select the compression-to-ventilation ratio of concurrent subject ventilation. Method 23 may be utilized for optimizing all forms of cardiopulmonary resuscitation, such as closed-chest CPR, open-chest cardiopulmonary resuscitation, and CPR which utilizes any mechanical adjunct. In this manner, method 23 may be utilized with mechanical resuscitators, ventricular assist devices, and cardiopulmonary bypass techniques performed during open-heart procedures. Thus, method 23 provides a feedback loop to monitor myocardial perfusion, titrate therapy, and optimize perfusion techniques during all forms of CPR.
  • Method 23 may also be utilized to select a defibrillation threshold, which is defined as the minimum amount of energy and/or current required to convert the cardiac rhythm from a ventricular fibrillation to a non- ventricular fibrillation rhythm.
  • a determination of the minimum amount of energy or current a defibrillator needs to deliver could be derived as a function of the value of F c and/or F p . This could help minimize myocardial injury and also save energy for the battery of defibrillators.
  • Method 23 may also be used to estimate the optimum waveform and/or paddle position to use when delivering a countershock.
  • Method 23 may be used to treat subjects experiencing involuntary cardiac arrest, but may also be used to restart a heart that has been intentionally placed into ventricular fibrillation for cardio- vascular surgery or the like. Although the heart is perfused during surgery, lactic acid and other products may accumulate in the myocardium. Method 23 provides a technique for ensuring optimum perfusion and that non-productive countershocks will not be administered.
  • a subject monitor apparatus 100 includes an analyzer 104 for determining at least one amplitude parameter of the ECG time-domain signal interval or frequency parameter of a power spectrum following fast Fourier analysis of the subject's ECG (Fig. 3).
  • Conditioning unit 102 amplifies, filters, and digitizes the subject's ECG.
  • a processor 106 resolves the values of the parameter or parameters determined by analyzer 104 into clinically useful characteristics of the subject's heart, which may be displayed on display 108, along with the values of the parameters themselves, if desired.
  • Signal conditioner 102 may be provided by an external apparatus, such as an ECG monitor or a defibrillator, or may be included with apparatus 100.
  • Apparatus 100 may be useful for a research monitor to display the results of experimental interventions on animal or human subjects or as a subject monitor to read out vital characteristics of the heart of a subject in an emergency room, critical care unit, or the like.
  • a treatment apparatus 200 includes a processor 206 that is capable of making a determination to administer an electrical countershock and to control a defibrillator 208 in applying the countershock to the subject (Fig. 4). This may include the timing, energy, current, waveform, or the like, of the countershock. Apparatus 200 may additionally include an output for controlling a resuscitator 210 or other mechanical- administering adjunct. Apparatus 200 may be built into defibrillator 208 in a compact housing along with a microcomputer to carry out the functions of conditioner 102, analyzer 104, and processor 206, or may be a separate unit. The above example is for illustration purposes only. It should be understood that apparatus 200 may include only a defibrillator, 208, only a resuscitator, 210, or both.
  • apparatus 100 may include an event marker in order to allow a particular event to be time-stamped in the apparatus, such as a drug administration or the like.
  • the present invention provides a method and an apparatus that may be incorporated into existing ECG monitors and/or defibrillators in order to provide manual, semi-automatic, or automatic subject treatment devices, as well as to be used as a stand-alone monitor.
  • the invention may be applied to subjects of all species, habitus, underlying pathophysiology, and duration of ischemia. Because the invention includes a reliable procedure for determining the ability of the subject's heart to be converted to a pulsatile rhythm following countershock, damage to the myocardium resulting from cumulative energy from one, or a succession, of countershocks may be avoided.
  • the present invention additionally provides the ability to regulate the level of therapeutic interventions and, thereby, avoid damage from unnecessary interventions or interventions greater than that required.
  • the invention additionally provides the ability to accurately monitor myocardial perfusion and, thus, the metabolic state of the subject's heart based upon the recognition that F c is positively correlated with myocardial perfusion pressure during CPR. Since F c and F p are predictive of successful outcomes from countershock which is dependent upon myocardial perfusion, then F p should also be positively correlated with myocardial perfusion pressure during CPR.
  • the parameters F c and F p in combination provide an especially reliable prediction of the ability of the subject's heart to be converted to a pulsatile rhythm following countershock.
  • EXAMPLE A retrospective analysis of ECG cassette recordings obtained during cardiac arrest of 55 human subjects with out-of-hospital cardiac arrest whose initial ECG rhythms were identified as ventricular fibrillation. Subjects were monitored with a semi-automatic defibrillator/ECG monitor equipped with an ECG and voice cassette recording, such as Model Heart Aid 1000, Heartstart 1000, or Heartstart 2000 marketed by Laerdal Corporation in Armonk, New York. The frequency bandwidth of the ECG recording was 1.7-20 Hz. The recorded ECG signals were digitized with an analog-to-digital converter, Model No. DT-2801A marketed by Data Translation, of Marlborough, Massachusetts.
  • the analog-to-digital conversion was done at 64 Hz and analyzed on an IBM compatible microcomputer utilizing a program written in commercial scientific software package language ASYST, Version 4.01, marketed by Keithley Instrument Company in Taunton, Massachusetts.
  • the ECG signals were processed in the same manner disclosed in United States Patent No. 5,077,667 to Charles G. Brown and Roger Dzwonczyk.
  • Each electrical countershock was identified on the ECG recording and a four-second epoch just prior to each countershock was analyzed.
  • Each time-domain signal epoch was transf o ⁇ ned into the frequency domain using a fast Fourier transform algorithm. Centroid frequency (F c ) and peak power frequency (F p ) were extracted from the resulting power spectrum.
  • SA and SA were extracted from the original time domain ECG epoch.
  • the portion of the ventricular fibrillation ECG signal extending from peak to the following adjacent trough is defined as a "wave.
  • Wave amplitude is the difference between the peak and trough amplitude of a wave.
  • the average wave amplitude was obtained by calculating the average of all peak-to-trough wave amplitudes in the epoch.
  • the average segment amplitude was obtained by calculating the average of the full- wave rectified signal epoch.
  • the peak and trough must have been at least 0.256 seconds apart in time.
  • the parameters WA and SA are reported in microvolts and provide an estimate of the average amplitude of a time-domain signal in the epoch.
  • each countershock was also recorded and paired with the corresponding parameter values.
  • a successful countershock was defined as the conversion of ventricular fibrillation to a supraventricular rhythm associated with a palpable pulse or blood pressure of any duration within two minutes of the countershock without ongoing CPR.
  • EMS Emergency Medical Services'
  • a countershock was eliminated from analysis if the ECG signal prior to the countershock contained identifiable artifact, such as interference from cardiopulmonary resuscitation, or other noise.
  • the subjects received a total of 324 countershocks. However, only 128 of the countershocks were free of artifact.
  • the term "sensitivity" of the parameter is the probability that the parameter will be equal to or greater than a specific value given that the subject is successfully countershocked.
  • the "specificity” of the parameter is the probability that the parameter will be less than a specific value given that the subject is not successfully countershocked.
  • the value of each parameter as a predictor of clinically relevant cardiac arrest outcomes was determined by calculating the area under the receiver operating characteristic (ROC) curve.
  • An ROC curve 50 of the parameter F c for an outcome of successful countershock is illustrated in Fig. 5.
  • the area under ROC curve 50 represents the probability to which F c can be used to predict successful countershock.
  • the area under curve 50 is 0.717.
  • ROC curve 52 of the parameter F p for an outcome of successful countershock is illustrated in Fig. 6.
  • the area under ROC curve 52 represents the probability to which F p can be used to predict success.
  • the area under curve 52 is 0.697.
  • a review of Figs. 5 and 6 illustrates the significant ability of the parameters to predict successful countershock of the subject.
  • the significant area under ROC curves 50 and 52 is in contrast to ROC curve 54 of the parameter SA, for an outcome of successful countershock (Fig. 7), and ROC curve 56 of the parameter WA (Fig. 8) for an outcome of successful countershock.
  • Curves 54 and 56 have significant negative as well as positive areas, which indicates the inability of the parameters SA and WA to predict successful countershock of the subject.
  • Table 2 illustrates a statistical analysis for the parameters F c and F p with a successful outcome defined as a return of spontaneous circulation more than two minutes after countershock:
  • Table 3 illustrates a statistical analysis for the parameters F c and F p with a successful outcome defined as a survival to admission to a hospital:
  • Table 4 illustrates a statistical analysis for the parameters F c and F p with a successful outcome defined as a survival to discharge from a hospital:
  • An ROC curve 76 of F c for the outcome of whether the subject ever experienced a return of spontaneous circulation is illustrated in Fig. 9.
  • the area under curve 76 is 0.767.
  • An ROC curve 78 of the parameter F p for the outcome of whether the subject ever experienced a return of spontaneous circulation, is illustrated in Fig. 10.
  • the area under curve 78 is 0.890.
  • An examination of the areas under curves 76 and 78 illustrates the significant predictive value of these parameters for return of spontaneous circulation ever.
  • An ROC curve 80 of the parameter F c for the successful outcome of survival to admission to a hospital is illustrated in Fig. 11.
  • the area under curve 80 is 0.656.
  • the ROC curve 82 of the parameter F p for the successful outcome of survival to admission to a hospital is illustrated in Fig. 12.
  • the area under curve 82 is 0.616.
  • An ROC curve 84 of the parameter F c for the successful outcome of survival to discharge from a hospital is illustrated in Fig. 13 and an ROC curve 86 of the parameter F p for survival to discharge is illustrated in Fig. 14.
  • the area under curve 84 is 0.886 and the area under curve 86 is 0.835.
  • the present invention provides a useful method and apparatus for both guiding interventions for subjects experiencing cardiac arrest as well as predicting the likelihood that particular interventions will be successful.
  • the invention has application in treating human subjects in cardiac arrest, it may also be used as a research monitor for evaluating the effect of interventions on human subjects, or used on other animal subjects, in which cardiac arrest is induced. Changes and modifications in the specifically described embodiments can be carried out without departing from the principles of the invention, which is intended to be limited only by the scope of the appended claims, as interpreted according to the principles of patent law including the doctrine of equivalents.

Landscapes

  • Electrotherapy Devices (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

Abstract

Cette invention concerne un procédé non invasif permettant de guider des interventions thérapeutiques chez un sujet atteint d'un arrêt cardiaque. Ce procédé consiste à connecter des électrodes au corps (22) du sujet et à mesurer un potentiel électrique analogique qui est proportionnel au potentiel électrique généré par le coeur du sujet. Un appareil (20) déterminant des paramètres de prédiction va échantillonner le potentiel analogique pendant un intervalle de temps donné afin d'obtenir un ensemble d'échantillons de domaine temporel. En transformant ces échantillons de domaine temporel en un spectre de puissance de domaine de fréquence, l'appareil (20) permet d'obtenir la répartition de puissance du potentiel électrique. Un ou plusieurs paramètres d'amplitude de l'intervalle du signal de domaine temporel d'ECG, ou un ou plusieurs paramètres de fréquence du spectre de puissance, sont ensuite déterminés et contrôlés. Ces paramètres permettent de prédire une issue de l'arrêt cardiaque dont souffre le sujet, qui soit pertinente sur le plan clinique. Une thérapie est ensuite appliquée au sujet à l'aide d'un défibrillateur (21) ou d'un réanimateur (25) en fonction des valeurs des paramètres.
EP95944683A 1995-12-28 1995-12-28 Controle et traitement non invasifs de sujets atteints d'arret cardiaque a l'aide de parametres d'ecg permettant de predire l'issue Ceased EP0874584A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1995/017022 WO1997024062A1 (fr) 1994-08-30 1995-12-28 Controle et traitement non invasifs de sujets atteints d'arret cardiaque a l'aide de parametres d'ecg permettant de predire l'issue

Publications (2)

Publication Number Publication Date
EP0874584A1 true EP0874584A1 (fr) 1998-11-04
EP0874584A4 EP0874584A4 (fr) 1999-02-03

Family

ID=22250393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95944683A Ceased EP0874584A4 (fr) 1995-12-28 1995-12-28 Controle et traitement non invasifs de sujets atteints d'arret cardiaque a l'aide de parametres d'ecg permettant de predire l'issue

Country Status (2)

Country Link
EP (1) EP0874584A4 (fr)
JP (1) JP2001519681A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111803054A (zh) * 2020-06-12 2020-10-23 中国人民解放军陆军军医大学 一种实时评估室颤信号质量和除颤成功率的方法与仪器

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310137B1 (no) * 1998-12-11 2001-05-28 Laerdal Medical As System for å måle og analysere HLR parametere for anvendelse med og av en ekstern defibrillator
WO2005112749A1 (fr) * 2004-05-12 2005-12-01 Zoll Medical Corporation Procede de recommandation pour rythme ecg

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019452A1 (fr) * 1990-06-20 1991-12-26 Cedars-Sinai Medical Center Procedes de detection et d'evaluation de troubles cardiaques
US5077667A (en) * 1989-07-10 1991-12-31 The Ohio State University Measurement of the approximate elapsed time of ventricular fibrillation and monitoring the response of the heart to therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077667A (en) * 1989-07-10 1991-12-31 The Ohio State University Measurement of the approximate elapsed time of ventricular fibrillation and monitoring the response of the heart to therapy
WO1991019452A1 (fr) * 1990-06-20 1991-12-26 Cedars-Sinai Medical Center Procedes de detection et d'evaluation de troubles cardiaques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9724062A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111803054A (zh) * 2020-06-12 2020-10-23 中国人民解放军陆军军医大学 一种实时评估室颤信号质量和除颤成功率的方法与仪器

Also Published As

Publication number Publication date
JP2001519681A (ja) 2001-10-23
EP0874584A4 (fr) 1999-02-03

Similar Documents

Publication Publication Date Title
US5683424A (en) Non-invasive monitoring and treatment of subjects in cardiac arrest using ECG parameters predictive of outcome
US5571142A (en) Non-invasive monitoring and treatment of subjects in cardiac arrest using ECG parameters predictive of outcome
US6171257B1 (en) Method and system for predicting the immediate success of a defibrillatory shock during cardiac arrest
US6438419B1 (en) Method and apparatus employing a scaling exponent for selectively defibrillating a patient
US7593772B2 (en) Methods and devices to characterize the probability of successful defibrillation and determine treatments for ventricular fibrillation
US10589112B2 (en) Dynamic energy selection for defibrillation
Brown et al. Signal analysis of the human electrocardiogram during ventricular fibrillation: frequency and amplitude parameters as predictors of successful countershock
Strohmenger et al. Analysis of the ventricular fibrillation ECG signal amplitude and frequency parameters as predictors of countershock success in humans
US10682067B2 (en) ECG rhythm advisory method
US20210252298A1 (en) Fast identification of shockable or non-shockable rhythms in ecg data
US5077667A (en) Measurement of the approximate elapsed time of ventricular fibrillation and monitoring the response of the heart to therapy
US8165673B2 (en) Devices, systems and methods for characterization of ventricular fibrillation and for treatment of ventricular fibrillation
US7805191B2 (en) CPR time indicator for a defibrillator data management system
Noc et al. Electrocardiographic prediction of the success of cardiac resuscitation
US7076299B2 (en) Method and apparatus for preventing heart tachyarrhythmia
EP2858557B1 (fr) Améliorations en matière de réanimation
US7269454B2 (en) Methods and devices to guide therapy for ventricular fibrillation based on waveform analysis and survival benefit analysis
US20150257709A1 (en) Dynamic energy selection for defibrillation
Achleitner et al. The effects of repeated doses of vasopressin or epinephrine on ventricular fibrillation in a porcine model of prolonged cardiopulmonary resuscitation
Coult et al. A method to detect presence of chest compressions during resuscitation using transthoracic impedance
Watson et al. A novel wavelet transform based analysis reveals hidden structure in ventricular fibrillation
Weaver et al. Automatic external defibrillators: importance of field testing to evaluate performance
EP0874584A1 (fr) Controle et traitement non invasifs de sujets atteints d'arret cardiaque a l'aide de parametres d'ecg permettant de predire l'issue
Liu et al. An acoustic method (Spectral Flux) to analyze ECG signals for optimizing timing for defibrillation in a porcine model of ventricular fibrillation
Tchoudovski et al. New approach in developing of the algorithms for resuscitation assistance

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980724

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT NL

A4 Supplementary search report drawn up and despatched

Effective date: 19981215

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE FR GB IT NL

17Q First examination report despatched

Effective date: 20020211

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20050407

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE